Podcast
MSL Talk: Tom Caravela, Mitchell D’Rozario
Finding Success as a Rare Diseases MSL
Summary
In this episode, Giovanni Passiatore delves into the complexities of working in the rare diseases arena as an MSL. Giovanni shares his extensive background and provides insights into the unique challenges faced in this field, including strategies for effective territory coverage and engaging with key opinion leaders. He highlights the critical role of patient identification and the emerging importance of patient diagnosis liaisons. Giovanni offers essential advice for aspiring MSLs, emphasizing the significance of humility, relationship-building, and business acumen. The episode wraps up with a focus on the resilience required for success in the MSL role and appreciation for the audience's engagement.
My guest today is Giovanni Passiatore, Head of US MSLs at Chiesi Rare Disease and he shares insights on how to find success as a Rare Diseases MSL
Giovanni discusses…
👉 What the industry considers “Rare Diseases” as a category
👉 Challenges Rare Diseases Medical Affairs/MSL teams face
👉 How the medical affairs strategy differs for a Rare Diseases company
👉 How metrics and KPIs may differ for Rare Disease MSLs
👉 Recommendations for Rare Disease MSLs to find success and become high performers in their territory
👉 What he looks for when hiring Rare Diseases MSLs
rare diseases MSL, medical science liaison challenges, key opinion leaders engagement, patient diagnosis liaisons, rare disease territory coverage
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Mitchell D’Rozario
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary
Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?
Article
J. Remon, R. García-Campelo, E. de Álava, R. Vera, J. L. Rodríguez-Peralto, Á. Rodríguez-Lescure, B. Bellosillo, P. Garrido, F. Rojo & R. Álvarez-Alegret